Pharmaceuticals, Biotechnology and Life Sciences
Ireland becomes the 13th country with Tilray medical cannabis products as company continues global expansion in Europe and increases access to patients in need
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
Trovagene has started erolling patients for its second phase study of onvansertib plus FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.
BioNTech pulled one of the largest private EU biotech funding events expands global shareholder base with $325 from investors
Catalyst adopts unified platform approach to immediately offer impactful and competitive services for biopharmaceutical companies New full service offerings adopt…
Microphyt secures one of the largest fundraising in the microalgae sector; The round was co-led by Sofinnova Partners and Bpifrance…
Neovacs has received a first payment of a total amount up to €702.000, for its preclinical development program AllergyVacs, within the grant awarded by the National Agency for Research (ANR), conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute.
Glenmark Pharmaceuticals got the final approval by the US FDA for its Ranolazine Extended-Release Tablets, generic version of Gilead’s Ranexa.
Karolinska Development’s drug developer Dilafor AB, focused on tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction, Karolinska said Tuesday in a press release.